Granulocyte-Colony Stimulating Factor 투여 후 발생한 돌발성 난청

Filgrastim^® (Granulocyte-colony stimulating factor, G-CSF) is generally used to promote the increase of neutrophils to patients with neutropenia during chemotherapy or donors for hematopoietic stem cell transplantation (HSCT). Its adverse effects were mainly reported as non-serious symptoms, such as back pain, headache, arthralgia and fever. A 29-year-old male was administered the Filgrastim as a HSCT donor. He accompanied left side hearing disturbance and tinnitus after 2 days from administration of the drug. He admitted to our department and underwent improvement of hearing after high dose steroid therapy. In this report, we describe a case of sudden sensorineural hearing loss (SSNHL) as an unreported adverse effect of G-CSF in the literature. (J Clinical Otolaryngol 2018;29:87-90)